Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA puts Omnitrope on hold

FDA has deferred a decision on the approval of Novartis' Omnitrope generic human growth hormone, pending resolution of scientific and legal issues

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE